Dolors Montserrat
Lobbying Activity
Meeting with MEDICINES FOR EUROPE
26 Nov 2025 · Review of the EU General Pharmaceutical Legislation
Meeting with Pharmaceutical Group of the European Union
25 Nov 2025 · Review of the EU General Pharmaceutical Legislation
Meeting with Pharmaceutical Group of the European Union
6 Nov 2025 · Review of the EU General Pharmaceutical Legislation
Meeting with Teva Pharmaceuticals Europe BV
17 Oct 2025 · Review of the EU General Pharmaceutical Legislation
Meeting with Aboca S.p.a. Società Agricola
14 Oct 2025 · Review of the EU General Pharmaceutical Legislation
Meeting with MEDICINES FOR EUROPE
10 Sept 2025 · Revision of the EU Pharmaceutical Directive
Meeting with Association of the European Self-Care Industry
4 Sept 2025 · Revision of the EU Pharmaceutical Directive
Meeting with Biocat, Fundació BioRegió de Catalunya
16 Jul 2025 · EU Biotechnologies hubs on Health
Meeting with Gilead Sciences
8 Jul 2025 · Review of the EU General Pharmaceutical Legislation
Meeting with Gilead Sciences
26 May 2025 · Cancer treatments and HIV vaccines
Meeting with Merck
26 May 2025 · New EU Pharmaceutical Legislation
Meeting with Affordable Medicines Europe
1 Apr 2025 · New EU Pharmaceutical Legislation
Meeting with MEDICINES FOR EUROPE
28 Mar 2025 · Urban Waste Water Treatment Directive
Meeting with HIPRA, S.A.
20 Mar 2025 · Vaccines and the EU preparedness strategy to Health crisis
Meeting with
19 Mar 2025 · New EU Pharmaceutical Legislation
Meeting with Cosmetics Europe
17 Mar 2025 · Current situation of the cosmetic industry in the EU
Meeting with Bayer AG
3 Dec 2024 · New EU Pharmaceutical Legislation
Meeting with EUROPEAN ORGANISATION FOR RARE DISEASES
19 Nov 2024 · Rare Diseases incidence in Europe
Meeting with MEDICINES FOR EUROPE
24 Oct 2024 · New EU Pharmaceutical Legislation
Meeting with European Diabetes Forum
23 Oct 2024 · Diabetes prevention and impact in the EU
Meeting with ExxonMobil Petroleum Chemical
22 Oct 2024 · EU Competitiveness and Ecological Transition
Meeting with Grupo Vall Companys
14 Oct 2024 · Sustainable Food production and Circular Economy
Meeting with Gilead Sciences
10 Oct 2024 · Prevention of infectious diseases
Meeting with Consejo General de Colegios oficiales de Médicos
9 Oct 2024 · Climate change impact on Health
Meeting with BioMarin UK Limited
8 Oct 2024 · New EU Pharmaceutical Legislation
Meeting with ALTRI, SGPS, S.A.
2 Oct 2024 · Circular Economy in the textile sector
Meeting with Teva Pharmaceuticals Europe BV
26 Sept 2024 · New EU Pharmaceutical Legislation
Meeting with International Air Transport Association
19 Sept 2024 · Sustainable aviation sector
Meeting with GSK
12 Sept 2024 · New EU Pharmaceutical Legislation
Meeting with Bayer AG
6 Mar 2024 · Revision of the pharmaceutical legislation
Meeting with Teva Pharmaceuticals Europe BV
4 Mar 2024 · Revision of the pharmaceutical legislation
Meeting with SANOFI
1 Mar 2024 · Future of pharmaceutical sector in Europe
Meeting with HIPRA, S.A.
20 Feb 2024 · EU Strategic Autonomy in vaccines manufacturing
Meeting with MEDICINES FOR EUROPE
16 Feb 2024 · Revision of the pharmaceutical legislation
Meeting with GSK
5 Feb 2024 · Revision of the pharmaceutical legislation
Meeting with Servier
13 Dec 2023 · Revision of the pharmaceutical legislation
Meeting with Boiron
11 Dec 2023 · Revision of the pharmaceutical legislation
Meeting with British American Tobacco
28 Nov 2023 · Health promotion
Meeting with
28 Nov 2023 · Revision of the pharmaceutical legislation
Meeting with SANOFI
17 Nov 2023 · Pharmaceutical Manufacturing in Europe
Meeting with Gilead Sciences
7 Nov 2023 · Revision of the pharmaceutical legislation
Meeting with
6 Nov 2023 · Revision of the pharmaceutical legislation
Meeting with Teva Pharmaceuticals Europe BV
23 Oct 2023 · Revision of the pharmaceutical legislation
Meeting with GSK
19 Oct 2023 · Revision of the pharmaceutical legislation
Meeting with Merck
1 Feb 2023 · Lessons learned on impact of COVID-19 pandemic
Meeting with Gilead Sciences
27 Jan 2023 · Lessons learned on impact of COVID-19 pandemic
Meeting with GSK
26 Jan 2023 · Lessons learned on impact of COVID-19 pandemic
Meeting with
12 Jan 2023 · Lessons learned on impact of COVID-19 pandemic
Meeting with EUROPEAN ORGANISATION FOR RARE DISEASES
11 Jan 2023 · Lessons learned on impact of COVID-19 pandemic
Meeting with MEDICINES FOR EUROPE
8 Dec 2022 · Lessons learned on impact of COVID-19 pandemic
Meeting with European Federation of Pharmaceutical Industries and Associations
7 Dec 2022 · Lessons learned on impact of COVID-19 pandemic
Meeting with
30 Nov 2022 · Lessons learned on impact of COVID-19 pandemic
Meeting with HIPRA, S.A.
29 Nov 2022 · Lessons learned on impact of COVID-19 pandemic
Meeting with European Healthcare Distribution Association
16 Nov 2022 · Lessons learned on impact of COVID-19 pandemic
Meeting with Novavax
15 Nov 2022 · Lessons learned on impact of COVID-19 pandemic
Meeting with Moderna, Inc.
10 Nov 2022 · Lessons learned on impact of COVID-19 pandemic
Meeting with Pfizer Inc.
8 Nov 2022 · Lessons learned on impact of COVID-19 pandemic
Meeting with Hologic BV
14 Sept 2022 · Cancer early diagnosis
Meeting with PROSEGUR COMPAÑÍA DE SEGURIDAD
7 Sept 2022 · AI and cybersecurity
Meeting with AstraZeneca PLC
2 Sept 2022 · National Healthcare Systems Sustainability
Meeting with Fresenius Kabi Deutschland GmbH
1 Sept 2022 · Revision of the Pharmaceutical Legislation
Meeting with ASOCIACIÓN ESPAÑOLA DE MEDICAMENTOS BIOSIMILARES
19 Nov 2021 · New Pharmaceutical Strategy for Europe
Meeting with ASOCIACIÓN NACIONAL EMPRESARIAL DE LA INDUSTRIA FARMACÉUTICA
3 Nov 2020 · New Pharmaceutical Strategy for Europe